Home

Tag: NASDAQ: EDIT

Editas Medicine (EDIT) Stock Rose 85% Since Release Of Positive Results Of Its New Research

The biotechnology company Editas Medicine Inc. (EDIT) stock rose more than 85% since its announcement of new data on the successful EDIT-301 gene therapy trial

BOVNEWS

BOVNews.com was originated in 2018 as a Company. Our team comprises Analysts and writers with the knowledge and expertise of Stock Markets and other sectors of Finance. The foremost objective is to deliver impartial opinion and detailed analysis on stock and markets. Our Research team is always keen to stay update on market highlights, earnings reports, mergers and acquisitions, analyst opinions, and pass on their knowledge and expertise to our reader.

Quick Links

Join our morning newsletter

Get the hottest stocks to trade every day before the market opens 100% free.